Last reviewed · How we verify
Placebo (for Naloxone)
A placebo is an inert substance with no active pharmacological mechanism, used as a control in clinical trials to measure the effect of naloxone independent of psychological expectation.
A placebo is an inert substance with no active pharmacological mechanism, used as a control in clinical trials to measure the effect of naloxone independent of psychological expectation. Used for Control arm in clinical trials evaluating naloxone efficacy.
At a glance
| Generic name | Placebo (for Naloxone) |
|---|---|
| Sponsor | Albert Einstein College of Medicine |
| Modality | Small molecule |
| Phase | FDA-approved |
Mechanism of action
Placebos contain no active drug and produce no direct biochemical effect. In the context of a naloxone trial, the placebo arm allows researchers to isolate the true pharmacological benefit of naloxone (opioid antagonism) from placebo response, natural disease progression, and other non-specific factors. This is a standard methodological tool in randomized controlled trials rather than a therapeutic agent.
Approved indications
- Control arm in clinical trials evaluating naloxone efficacy
Common side effects
Key clinical trials
- A Phase 2 Safety, Tolerability, PK, and Efficacy Study of CS-1103 Following Fentanyl Challenge With Naloxone Blockade (PHASE2)
- Lemborexant Augmentation of Naltrexone for Alcohol Craving and Sleep (PHASE3)
- Low-dose Naltrexone for Post-COVID Fatigue Syndrome (PHASE2)
- Combination Gerotherapeutic Interventions for Healthspan Improvement (PHASE3)
- Combination Therapy for Alcohol Use Disorder (PHASE2)
- Neural Mechanisms of Immersive Virtual Reality in Chronic Pain (PHASE1, PHASE2)
- Evaluate the Efficacy and Safety of Naltrexone Hydrochloride Implant in Patients With Alcohol Use Disorder (PHASE3)
- Rapid Antidepressant Improvement Secondary to Excitatory Brain Responses (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo (for Naloxone) CI brief — competitive landscape report
- Placebo (for Naloxone) updates RSS · CI watch RSS
- Albert Einstein College of Medicine portfolio CI